
On Thursday evening, the medtech company lowered its guidance, as the covid-19 pandemic continues to affect the number of operations being performed while also disrupting the firm's supply chain, according to an Ambu press release.
Now, Ambu expects to realize organic growth in 2021/2022 at around 17 percent compared to 17-20 percent previously forecast. It predicts that the earnings before interest an taxes will be around 10 percent, compared to 11-12 percent predicted previously.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app